This Article  • Full text  • PDF  • Author in the Room Audio  • Correction  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in JAMA  Social Bookmarking   What's this?

The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial

Victor G. Vogel, MD, MHS; Joseph P. Costantino, DrPH; D. Lawrence Wickerham, MD; Walter M. Cronin, MPH; Reena S. Cecchini, MS; James N. Atkins, MD; Therese B. Bevers, MD; Louis Fehrenbacher, MD; Eduardo R. Pajon, Jr, MD; James L. Wade III, MD; André Robidoux, MD; Richard G. Margolese, MD, CM; Joan James, PA-C; Scott M. Lippman, MD; Carolyn D. Runowicz, MD; Patricia A. Ganz, MD; Steven E. Reis, MD; Worta McCaskill-Stevens, MD; Leslie G. Ford, MD; V. Craig Jordan, PhD, DSc; Norman Wolmark, MD; for the National Surgical Adjuvant Breast and Bowel Project (NSABP)

JAMA. 2006;295:(doi:10.1001/jama.295.23.joc60074).

Context  Tamoxifen is approved for the reduction of breast cancer risk, and raloxifene has demonstrated a reduced risk of breast cancer in trials of older women with osteoporosis.

Objective  To compare the relative effects and safety of raloxifene and tamoxifen on the risk of developing invasive breast cancer and other disease outcomes.

Design, Setting, and Patients  The National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial, a prospective, double-blind, randomized clinical trial conducted beginning July 1, 1999, in nearly 200 clinical centers throughout North America, with final analysis initiated after at least 327 incident invasive breast cancers were diagnosed. Patients were 19 747 postmenopausal women of mean age 58.5 years with increased 5-year breast cancer risk (mean risk, 4.03% [SD, 2.17%]). Data reported are based on a cutoff date of December 31, 2005.

Intervention  Oral tamoxifen (20 mg/d) or raloxifene (60 mg/d) over 5 years.

Main Outcome Measures  Incidence of invasive breast cancer, uterine cancer, noninvasive breast cancer, bone fractures, thromboembolic events.

Results  There were 163 cases of invasive breast cancer in women assigned to tamoxifen and 168 in those assigned to raloxifene (incidence, 4.30 per 1000 vs 4.41 per 1000; risk ratio [RR], 1.02; 95% confidence interval [CI], 0.82-1.28). There were fewer cases of noninvasive breast cancer in the tamoxifen group (57 cases) than in the raloxifene group (80 cases) (incidence, 1.51 vs 2.11 per 1000; RR, 1.40; 95% CI, 0.98-2.00). There were 36 cases of uterine cancer with tamoxifen and 23 with raloxifene (RR, 0.62; 95% CI, 0.35-1.08). No differences were found for other invasive cancer sites, for ischemic heart disease events, or for stroke. Thromboembolic events occurred less often in the raloxifene group (RR, 0.70; 95% CI, 0.54-0.91). The number of osteoporotic fractures in the groups was similar. There were fewer cataracts (RR, 0.79; 95% CI, 0.68-0.92) and cataract surgeries (RR, 0.82; 95% CI, 0.68-0.99) in the women taking raloxifene. There was no difference in the total number of deaths (101 vs 96 for tamoxifen vs raloxifene) or in causes of death.

Conclusions  Raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and has a lower risk of thromboembolic events and cataracts but a nonstatistically significant higher risk of noninvasive breast cancer. The risk of other cancers, fractures, ischemic heart disease, and stroke is similar for both drugs.

Trial Registration  clinicaltrials.gov Identifier: NCT00003906

Published online June 5, 2006 (doi:10.1001/jama.295.23.joc60074).

Author Affiliations: Magee-Womens Hospital, University of Pittsburgh School of Medicine (Dr Vogel) and Graduate School of Public Health (Dr Costantino), University of Pittsburgh, Pittsburgh, Pa; National Surgical Adjuvant Breast and Bowel Project (NSABP) Operations and Biostatistical Centers, Pittsburgh (Drs Costantino, Wickerham, and Wolmark and Mr Cronin and Ms Cecchini); Allegheny General Hospital, Pittsburgh (Drs Wickerham and Wolmark); Southeast Cancer Control Consortium, Winston-Salem, NC (Dr Atkins); University of Texas M. D. Anderson Cancer Center, Houston (Drs Bevers and Lippman); Kaiser Permanente Northern California, Vallejo (Dr Fehrenbacher); Colorado CCOP, Denver Veterans Medical Center, Denver (Dr Pajon); Central Illinois CCOP, Decatur (Dr Wade); Centre hospitalier de l’Université de Montréal, Montréal, Quebec (Dr Robidoux); Jewish General Hospital, McGill University, Montréal (Dr Margolese); Fox Chase Cancer Center, Philadelphia, Pa (Ms James and Dr Jordan); University of Connecticut Health Center, Neag Comprehensive Cancer Center, Farmington (Dr Runowicz); UCLA Schools of Public Health and Medicine and Jonsson Comprehensive Cancer Center, Los Angeles, Calif (Dr Ganz); University of Pittsburgh, Pittsburgh (Dr Reis); and National Cancer Institute/National Institutes of Health, Bethesda, Md (Drs McCaskill-Stevens and Ford).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Raloxifene vs Tamoxifen

JAMA. ;297():263-264.
FULL TEXT  

Raloxifene vs Tamoxifen--Reply
and
JAMA. ;297():264-264.
FULL TEXT  

RELATED ARTICLES

Selective Estrogen Receptor Modulators and Prevention of Invasive Breast Cancer
and
JAMA. ;295():2784-2786.
FULL TEXT  

Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial
, , , , , , , , , , , and
JAMA. ;295():2742-2751.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effects of Tamoxifen and Raloxifene on Memory and Other Cognitive Abilities: Cognition in the Study of Tamoxifen and Raloxifene
Legault et al.
JCO 2009;27:5144-5152.
ABSTRACT | FULL TEXT  

Exploring the Impact of the Hormonal Milieu on Cognitive Functioning
Castellon and Ganz
JCO 2009;27:5119-5121.
FULL TEXT  

A Novel Look into Estrogen Receptor-Negative Breast Cancer Prevention with the Natural, Multifunctional Signal Transduction Inhibitor Deguelin
Rodenberg and Brown
Cancer Prevention Research 2009;2:915-918.
ABSTRACT | FULL TEXT  

Rethinking Screening for Breast Cancer and Prostate Cancer
Esserman et al.
JAMA 2009;302:1685-1692.
ABSTRACT | FULL TEXT  

Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer
Nelson et al.
ANN INTERN MED 2009;0:0000605-200911170-00147v1-E-147.
ABSTRACT | FULL TEXT  

The aryl hydrocarbon receptor as a target for estrogen receptor-negative breast cancer chemotherapy
Zhang et al.
Endocr Relat Cancer 2009;16:835-844.
ABSTRACT | FULL TEXT  

Lifestyle Interventions in the Prevention and Treatment of Cancer
Brown et al.
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2009;3:337-348.
ABSTRACT  

Is tamoxifen a genotoxic carcinogen in women?
Brown
Mutagenesis 2009;24:391-404.
ABSTRACT | FULL TEXT  

Pharmacogenetics of Solid Tumors: Directed Therapy in Breast, Lung, and Colorectal Cancer: A Paper from the 2008 William Beaumont Hospital Symposium on Molecular Pathology
Snozek et al.
J. Mol. Diagn. 2009;11:381-389.
ABSTRACT | FULL TEXT  

American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction
Visvanathan et al.
JCO 2009;27:3235-3258.
ABSTRACT | FULL TEXT  

Cancer Prevention: From 1727 to Milestones of the Past 100 Years
Lippman and Hawk
Cancer Res. 2009;69:5269-5284.
ABSTRACT | FULL TEXT  

Mixed Tocopherols Prevent Mammary Tumorigenesis by Inhibiting Estrogen Action and Activating PPAR-{gamma}
Lee et al.
Clin. Cancer Res. 2009;15:4242-4249.
ABSTRACT | FULL TEXT  

Cancer Prevention Research: Back to the Future
Lippman
Cancer Prevention Research 2009;2:503-513.
FULL TEXT  

Physical Activity, Weight Control, and Breast Cancer Risk and Survival: Clinical Trial Rationale and Design Considerations
Ballard-Barbash et al.
JNCI J Natl Cancer Inst 2009;101:630-643.
ABSTRACT | FULL TEXT  

No Effect of Aspirin on Mammographic Density in a Randomized Controlled Clinical Trial
McTiernan et al.
Cancer Epidemiol. Biomarkers Prev. 2009;18:1524-1530.
ABSTRACT | FULL TEXT  

Reproducibility of Random Periareolar Fine Needle Aspiration in a Multi-Institutional Cancer and Leukemia Group B (CALGB) Cross-Sectional Study
Ibarra-Drendall et al.
Cancer Epidemiol. Biomarkers Prev. 2009;18:1379-1385.
ABSTRACT | FULL TEXT  

A Randomized Phase II Chemoprevention Trial of 13-CIS Retinoic Acid with Or without {alpha} Tocopherol or Observation in Subjects at High Risk for Lung Cancer
Kelly et al.
Cancer Prevention Research 2009;2:440-449.
ABSTRACT | FULL TEXT  

The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression
Liu et al.
Molecular Cancer Therapeutics 2009;8:1207-1217.
ABSTRACT | FULL TEXT  

Use of 5-{alpha}-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline
Kramer et al.
JCO 2009;27:1502-1516.
ABSTRACT | FULL TEXT  

Prevention of Breast Cancer in Postmenopausal Women: Approaches to Estimating and Reducing Risk
Cummings et al.
JNCI J Natl Cancer Inst 2009;101:384-398.
ABSTRACT | FULL TEXT  

Questioning the Accuracy of a Recent Review of Osteoporosis Medications
Kuhl et al.
ANN INTERN MED 2009;150:423-424.
FULL TEXT  

Questioning the Accuracy of a Recent Review of Osteoporosis Medications
MacLean and Suttorp
ANN INTERN MED 2009;150:424-425.
FULL TEXT  

American Society of Clinical Oncology Policy Statement: The Role of the Oncologist in Cancer Prevention and Risk Assessment
Zon et al.
JCO 2009;27:986-993.
ABSTRACT | FULL TEXT  

A Century of Deciphering the Control Mechanisms of Sex Steroid Action in Breast and Prostate Cancer: The Origins of Targeted Therapy and Chemoprevention
Jordan
Cancer Res. 2009;69:1243-1254.
ABSTRACT | FULL TEXT  

Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections
Miguel et al.
J Antimicrob Chemother 2009;63:365-368.
ABSTRACT | FULL TEXT  

New Therapies for Osteoporosis
Hegge et al.
Journal of Pharmacy Practice 2009;22:53-64.
ABSTRACT  

BRCA1/2-Associated and Sporadic Breast Cancers: Fellow Travelers or Not?
Garber
Cancer Prevention Research 2009;2:100-103.
FULL TEXT  

Ductal Carcinoma in Situ: State of the Science and Roadmap to Advance the Field
Kuerer et al.
JCO 2009;27:279-288.
ABSTRACT | FULL TEXT  

Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT)
Lippman et al.
JAMA 2009;301:39-51.
ABSTRACT | FULL TEXT  

Women at High Risk for Breast Cancer--What the Primary Care Provider Needs to Know
Afonso
J Am Board Fam Med 2009;22:43-50.
ABSTRACT | FULL TEXT  

Structural Modulation of Oxidative Metabolism in Design of Improved Benzothiophene Selective Estrogen Receptor Modulators
Qin et al.
Drug Metab. Dispos. 2009;37:161-169.
ABSTRACT | FULL TEXT  

Estrogen Receptor-{beta} as a Potential Target for Colon Cancer Prevention: Chemoprevention of Azoxymethane-Induced Colon Carcinogenesis by Raloxifene in F344 Rats
Janakiram et al.
Cancer Prevention Research 2009;2:52-59.
ABSTRACT | FULL TEXT  

Effect of Raloxifene on Stroke and Venous Thromboembolism According to Subgroups in Postmenopausal Women at Increased Risk of Coronary Heart Disease
Mosca et al.
Stroke 2009;40:147-155.
ABSTRACT | FULL TEXT  

Update on JAMA-EXPRESS: Rapid Review and Publication
Fontanarosa and DeAngelis
JAMA 2008;300:2920-2921.
FULL TEXT  

Physicians' Experiences With BRCA1/2 Testing in Community Settings
Keating et al.
JCO 2008;26:5789-5796.
ABSTRACT | FULL TEXT  

Chemoprevention of breast cancer
Thomsen and Kolesar
Am J Health Syst Pharm 2008;65:2221-2228.
ABSTRACT | FULL TEXT  

Assessing Toxicity in Cancer Chemoprevention Trials: The Other Side of the Coin
Goodman
Cancer Prevention Research 2008;1:499-502.
FULL TEXT  

Tamoxifen Prevents Premalignant Changes of Breast, but not Ovarian, Cancer in Rats at High Risk for Both Diseases
Ting et al.
Cancer Prevention Research 2008;1:546-553.
ABSTRACT | FULL TEXT  

Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism
Payre et al.
Molecular Cancer Therapeutics 2008;7:3707-3718.
ABSTRACT | FULL TEXT  

Assessment of the Accuracy of the Gail Model in Women With Atypical Hyperplasia
Pankratz et al.
JCO 2008;26:5374-5379.
ABSTRACT | FULL TEXT  

Calcium Plus Vitamin D Supplementation and the Risk of Breast Cancer
Chlebowski et al.
JNCI J Natl Cancer Inst 2008;100:1581-1591.
ABSTRACT | FULL TEXT  

Tamoxifen Use and Osteoporotic Fracture Risk: A Population-Based Analysis
Cooke et al.
JCO 2008;26:5227-5232.
ABSTRACT | FULL TEXT  

Opportunities and Strategies for Breast Cancer Prevention Through Risk Reduction
Mahoney et al.
CA Cancer J Clin 2008;0:CA.2008.0016v1-CA.2008.0016.
ABSTRACT | FULL TEXT  

Possible Difference in Frequencies of Genetic Polymorphisms of Estrogen Receptor {alpha}, Estrogen Metabolism and P53 Genes Between Estrogen Receptor-positive and -negative Breast Cancers
Hamaguchi et al.
Jpn J Clin Oncol 2008;38:734-742.
ABSTRACT | FULL TEXT  

Gemini Vitamin D Analogues Inhibit Estrogen Receptor-Positive and Estrogen Receptor-Negative Mammary Tumorigenesis without Hypercalcemic Toxicity
Lee et al.
Cancer Prevention Research 2008;1:476-484.
ABSTRACT | FULL TEXT  

Osteoporosis Primer for the Vertebroplasty Practitioner: Expanding the Focus Beyond Needles and Cement
Kearns and Kallmes
Am. J. Neuroradiol. 2008;29:1816-1822.
ABSTRACT | FULL TEXT  

Regulation of Estrogenic Effects by Beclin 1 in Breast Cancer Cells
John et al.
Cancer Res. 2008;68:7855-7863.
ABSTRACT | FULL TEXT  

Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians
Qaseem et al.
ANN INTERN MED 2008;149:404-415.
ABSTRACT | FULL TEXT  

Impaired Tamoxifen Metabolism Reduces Survival in Familial Breast Cancer Patients
Newman et al.
Clin. Cancer Res. 2008;14:5913-5918.
ABSTRACT | FULL TEXT  

Impact of Raloxifene or Tamoxifen Use on Endometrial Cancer Risk: A Population-Based Case-Control Study
DeMichele et al.
JCO 2008;26:4151-4159.
ABSTRACT | FULL TEXT  

Management of breast cancer--Part I
Turner and Jones
BMJ 2008;337:a421-a421.
FULL TEXT  

Effect of Raloxifene on Mammographic Density and Breast Magnetic Resonance Imaging in Premenopausal Women at Increased Risk for Breast Cancer
Eng-Wong et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:1696-1701.
ABSTRACT | FULL TEXT  

Impact of Economic, Regulatory, and Patent Policies on Innovation in Cancer Chemoprevention
Grabowski and Moe
Cancer Prevention Research 2008;1:84-90.
ABSTRACT | FULL TEXT  

The 38th David A. Karnofsky Lecture: The Paradoxical Actions of Estrogen in Breast Cancer--Survival or Death?
Jordan
JCO 2008;26:3073-3082.
ABSTRACT | FULL TEXT  

Reduced Incidence of Invasive Breast Cancer With Raloxifene Among Women at Increased Coronary Risk
Grady et al.
JNCI J Natl Cancer Inst 2008;100:854-861.
ABSTRACT | FULL TEXT  

The Rise of Raloxifene and the Fall of Invasive Breast Cancer
Jordan
JNCI J Natl Cancer Inst 2008;100:831-833.
FULL TEXT  

Review of Comparative Effectiveness of Treatments to Prevent Fractures
Stock et al.
ANN INTERN MED 2008;148:885-885.
FULL TEXT  

Review of Comparative Effectiveness of Treatments to Prevent Fractures
MacLean et al.
ANN INTERN MED 2008;148:887-887.
FULL TEXT  

Osteoporosis: Management and Treatment Strategies for Orthopaedic Surgeons
Gehrig et al.
JBJS 2008;90:1362-1374.
FULL TEXT  

Urinary Metalloproteinases: Noninvasive Biomarkers for Breast Cancer Risk Assessment
Pories et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:1034-1042.
ABSTRACT | FULL TEXT  

Estrogen Receptor Regulation of Carbonic Anhydrase XII through a Distal Enhancer in Breast Cancer
Barnett et al.
Cancer Res. 2008;68:3505-3515.
ABSTRACT | FULL TEXT  

Optimizing Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: Treating the Right Patients for the Right Length of Time
Lin and Winer
JCO 2008;26:1919-1921.
FULL TEXT  

55-Year-Old Woman With Menopausal Symptoms and a Family History of Breast Cancer
Mallin and Pavlicek
Mayo Clin Proc. 2008;83:485-488.
FULL TEXT  

Menopausal symptoms and adjuvant therapy-associated adverse events
Hadji
Endocr Relat Cancer 2008;15:73-90.
ABSTRACT | FULL TEXT  

ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults
MacLaughlin and Raehl
Am J Health Syst Pharm 2008;65:343-357.
FULL TEXT  

Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis
MacLean et al.
ANN INTERN MED 2008;148:197-213.
ABSTRACT | FULL TEXT  

Differential Regulation of Native Estrogen Receptor-Regulatory Elements by Estradiol, Tamoxifen, and Raloxifene
Levy et al.
Mol. Endocrinol. 2008;22:287-303.
ABSTRACT | FULL TEXT  

Publication of Clinical Trials in JAMA: Information for Authors
Fontanarosa and DeAngelis
JAMA 2008;299:95-96.
FULL TEXT  

Selective Estrogen-Receptor Modulators and Antihormonal Resistance in Breast Cancer
Jordan and O'Malley
JCO 2007;25:5815-5824.
ABSTRACT | FULL TEXT  

Projecting Individualized Absolute Invasive Breast Cancer Risk in African American Women
Gail et al.
JNCI J Natl Cancer Inst 2007;99:1782-1792.
ABSTRACT | FULL TEXT  

Predicting Risk of Breast Cancer in Postmenopausal Women by Hormone Receptor Status
Chlebowski et al.
JNCI J Natl Cancer Inst 2007;99:1695-1705.
ABSTRACT | FULL TEXT  

Compliance With Patient-Reported Outcomes in Multicenter Clinical Trials: Methodologic and Practical Approaches
Land et al.
JCO 2007;25:5113-5120.
ABSTRACT | FULL TEXT  

Patient-Reported Outcomes Assessment in Cancer Trials: Taking Stock, Moving Forward
Lipscomb et al.
JCO 2007;25:5133-5140.
ABSTRACT | FULL TEXT  

Proliferative Changes in Chemoprevention Trials: Learning From Secondary Endpoints
Szabo
JNCI J Natl Cancer Inst 2007;99:1565-1567.
FULL TEXT  

Phase III Double-Blind Trial of Arzoxifene Compared With Tamoxifen for Locally Advanced or Metastatic Breast Cancer
Deshmane et al.
JCO 2007;25:4967-4973.
ABSTRACT | FULL TEXT  

Tamoxifen or Raloxifene for Breast Cancer Chemoprevention: A Tale of Two Choices Point
Jordan
Cancer Epidemiol. Biomarkers Prev. 2007;16:2207-2209.
FULL TEXT  

Tamoxifen or Raloxifene in Postmenopausal Women for Prevention of Breast Cancer: A Tale of Two Choices Counterpoint
Fabian
Cancer Epidemiol. Biomarkers Prev. 2007;16:2210-2212.
FULL TEXT  

A Midpoint Assessment of the American Cancer Society Challenge Goal to Decrease Cancer Incidence by 25% Between 1992 and 2015
Sedjo et al.
CA Cancer J Clin 2007;57:326-340.
ABSTRACT | FULL TEXT  

The Rexinoid LG100268 Prevents the Development of Preinvasive and Invasive Estrogen Receptor Negative Tumors in MMTV-erbB2 Mice
Li et al.
Clin. Cancer Res. 2007;13:6224-6231.
ABSTRACT | FULL TEXT  

Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research
Hoque et al.
Cancer Res. 2007;67:8989-8993.
ABSTRACT | FULL TEXT  

Randomized Dose-Ranging Trial of Tamoxifen at Low Doses in Hormone Replacement Therapy Users
Decensi et al.
JCO 2007;25:4201-4209.
ABSTRACT | FULL TEXT  

Ontology, Oncology, and Preventive Economies: Developing Drugs for Cancer Prevention
Vogel
Clin. Cancer Res. 2007;13:5227-5228.
FULL TEXT  

Follow-up of Patients with Early Breast Cancer
Sakemi et al.
NEJM 2007;357:1052-1053.
FULL TEXT  

Can Statins Pass the Aspirin Litmus Test in Cancer?
Kauh and Khuri
JCO 2007;25:3395-3396.
FULL TEXT